Cargando…
Neurocognitive outcomes of tuberculous meningitis in a primarily HIV-positive Ugandan cohort
Background: The toll of tuberculous meningitis (TBM) in both mortality and disability is considerable, but advancements in rehabilitation have the potential to improve the functional abilities and the quality of survivors’ lives. However, the typical phenotype of neurocognitive impairment in TBM sur...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334841/ https://www.ncbi.nlm.nih.gov/pubmed/35949653 http://dx.doi.org/10.12688/wellcomeopenres.16967.2 |
_version_ | 1784759195174699008 |
---|---|
author | Quinn, Carson M Kasibante, John Namudde, Alice Bangdiwala, Ananta S Kabahubya, Mable Nakasujja, Noeline Lofgren, Sarah Elliott, Alison Boulware, David R Meya, David B Cresswell, Fiona V |
author_facet | Quinn, Carson M Kasibante, John Namudde, Alice Bangdiwala, Ananta S Kabahubya, Mable Nakasujja, Noeline Lofgren, Sarah Elliott, Alison Boulware, David R Meya, David B Cresswell, Fiona V |
author_sort | Quinn, Carson M |
collection | PubMed |
description | Background: The toll of tuberculous meningitis (TBM) in both mortality and disability is considerable, but advancements in rehabilitation have the potential to improve the functional abilities and the quality of survivors’ lives. However, the typical phenotype of neurocognitive impairment in TBM survivors remains unstudied in HIV-predominant populations in sub-Saharan Africa. Methods: We tested 36 survivors of TBM in Uganda with a comprehensive battery of neurocognitive assessments at 8 and 24 weeks after diagnosis, and compared results to a representative cohort of HIV-uninfected Ugandans. Results: While participants had a broad range of impairments at eight weeks, there was marked improvement by 24 weeks, when a phenotype of impairment including deficits in motor functioning, verbal learning and memory, processing speed, and executive function emerged. These deficits were present despite good clinician-rated functional status. The majority (23/27, 85%) had evidence of moderate to severe depression at week 8, and at week 24 (18/24, 75%). Conclusion: These findings highlight the need for more comprehensive neurocognitive assessment in the survivors of TBM, and further investment in and study of rehabilitation, including management of depression, to improve long-term outcomes in this population. |
format | Online Article Text |
id | pubmed-9334841 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | F1000 Research Limited |
record_format | MEDLINE/PubMed |
spelling | pubmed-93348412022-08-09 Neurocognitive outcomes of tuberculous meningitis in a primarily HIV-positive Ugandan cohort Quinn, Carson M Kasibante, John Namudde, Alice Bangdiwala, Ananta S Kabahubya, Mable Nakasujja, Noeline Lofgren, Sarah Elliott, Alison Boulware, David R Meya, David B Cresswell, Fiona V Wellcome Open Res Research Article Background: The toll of tuberculous meningitis (TBM) in both mortality and disability is considerable, but advancements in rehabilitation have the potential to improve the functional abilities and the quality of survivors’ lives. However, the typical phenotype of neurocognitive impairment in TBM survivors remains unstudied in HIV-predominant populations in sub-Saharan Africa. Methods: We tested 36 survivors of TBM in Uganda with a comprehensive battery of neurocognitive assessments at 8 and 24 weeks after diagnosis, and compared results to a representative cohort of HIV-uninfected Ugandans. Results: While participants had a broad range of impairments at eight weeks, there was marked improvement by 24 weeks, when a phenotype of impairment including deficits in motor functioning, verbal learning and memory, processing speed, and executive function emerged. These deficits were present despite good clinician-rated functional status. The majority (23/27, 85%) had evidence of moderate to severe depression at week 8, and at week 24 (18/24, 75%). Conclusion: These findings highlight the need for more comprehensive neurocognitive assessment in the survivors of TBM, and further investment in and study of rehabilitation, including management of depression, to improve long-term outcomes in this population. F1000 Research Limited 2022-03-03 /pmc/articles/PMC9334841/ /pubmed/35949653 http://dx.doi.org/10.12688/wellcomeopenres.16967.2 Text en Copyright: © 2022 Quinn CM et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Quinn, Carson M Kasibante, John Namudde, Alice Bangdiwala, Ananta S Kabahubya, Mable Nakasujja, Noeline Lofgren, Sarah Elliott, Alison Boulware, David R Meya, David B Cresswell, Fiona V Neurocognitive outcomes of tuberculous meningitis in a primarily HIV-positive Ugandan cohort |
title | Neurocognitive outcomes of tuberculous meningitis in a primarily HIV-positive Ugandan cohort |
title_full | Neurocognitive outcomes of tuberculous meningitis in a primarily HIV-positive Ugandan cohort |
title_fullStr | Neurocognitive outcomes of tuberculous meningitis in a primarily HIV-positive Ugandan cohort |
title_full_unstemmed | Neurocognitive outcomes of tuberculous meningitis in a primarily HIV-positive Ugandan cohort |
title_short | Neurocognitive outcomes of tuberculous meningitis in a primarily HIV-positive Ugandan cohort |
title_sort | neurocognitive outcomes of tuberculous meningitis in a primarily hiv-positive ugandan cohort |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334841/ https://www.ncbi.nlm.nih.gov/pubmed/35949653 http://dx.doi.org/10.12688/wellcomeopenres.16967.2 |
work_keys_str_mv | AT quinncarsonm neurocognitiveoutcomesoftuberculousmeningitisinaprimarilyhivpositiveugandancohort AT kasibantejohn neurocognitiveoutcomesoftuberculousmeningitisinaprimarilyhivpositiveugandancohort AT namuddealice neurocognitiveoutcomesoftuberculousmeningitisinaprimarilyhivpositiveugandancohort AT bangdiwalaanantas neurocognitiveoutcomesoftuberculousmeningitisinaprimarilyhivpositiveugandancohort AT kabahubyamable neurocognitiveoutcomesoftuberculousmeningitisinaprimarilyhivpositiveugandancohort AT nakasujjanoeline neurocognitiveoutcomesoftuberculousmeningitisinaprimarilyhivpositiveugandancohort AT lofgrensarah neurocognitiveoutcomesoftuberculousmeningitisinaprimarilyhivpositiveugandancohort AT elliottalison neurocognitiveoutcomesoftuberculousmeningitisinaprimarilyhivpositiveugandancohort AT boulwaredavidr neurocognitiveoutcomesoftuberculousmeningitisinaprimarilyhivpositiveugandancohort AT meyadavidb neurocognitiveoutcomesoftuberculousmeningitisinaprimarilyhivpositiveugandancohort AT cresswellfionav neurocognitiveoutcomesoftuberculousmeningitisinaprimarilyhivpositiveugandancohort |